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Abstract With the advance in chromatin immunoprecipita-
tion followed byhigh-throughput sequencing, there has been a
dramatic increase in our understanding of distal enhancer
function. In the developing heart, the identification and
characterisation of such enhancers have deepened our
knowledge of the mechanisms of transcriptional regulation
that drives cardiac differentiation. With next-generation
sequencing techniques becoming widely accessible, the
quantity of data describing the genome-wide distribution of
cardiac-specific transcription factor and chromatin modifiers
has rapidly increased and it is now becoming clear that the
usage of enhancers is highly dynamic and complex, both
during the development and in the adult. The identification of
those enhancers has revealed new insights into the transcrip-
tional mechanisms of how tissue-specific gene expression
patterns are established, maintained, and change dynamically
during development and upon physiological stress.
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Introduction
The development of the four-chambered heart involves
coordinate differentiation of multiple cardiac cell types,
such changes occurring, whilst the embryonic organ
maintains its essential function pumping blood through the
developing embryo [1–3]. The transition between different
differentiation states of cardiac progenitors during heart
morphogenesis is the result of a tightly coordinated pro-
cess, regulated at the transcriptional level. In that context,
the non-coding part of the genome has recently been shown
to encode a large collection of enhancers and associated
non-coding RNAs (for example micro RNAs or long non-
coding RNAs) with regulatory functions within the gene
regulatory network driving heart development [4, 5]. Dis-
tant enhancers control the dynamic expression of cardiac-
specific genes and any disruption of such controls can lead
to a large variety of congenital heart defects (CHD). CHD
are the most common type of birth defect, affecting 10 %
live births [6, 7]. Moreover, mutations within non-coding
elements, such as enhancers, have been shown to disrupt
heart development [8–10]. Our increased understanding of
the transcriptional processes occurring during cardiac
development has spurred efforts to identify the mecha-
nisms that would allow the generation of cardiomyocytes
in vitro in numbers large enough for therapeutic use.
Efforts have focused either on differentiating embryonic
stem cells, or using induced pluripotent stem cells, termi-
nally differentiated cells which have been reprogrammed
through the introduction of a defined set of genes [11–13].
After describing the common strategies used to identify
cardiac enhancers and the difficulty in the design and
interpretation of ChIP-seq experiments, we will summarise
the state of our knowledge on the dynamics of enhancer
usage during the cardiac development and differentiation.
Identification of cardiac enhancers
Gene expression is regulated through the integrated action
of different types of cis-regulatory elements, such as
distal enhancers [14, 15]. Classically, enhancers are
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defined as non-coding DNA elements that can increase
the transcription of genes located in cis. With a significant
role in regulating gene expression, the identification and
location in the genome of those enhancers have been the
focus of many studies in the cardiovascular development
[16].
However, by their nature, the identification of such
enhancers is challenging. For example, their location rel-
ative to the target gene, or genes, is highly variable and
they can function in an orientation-independent manner.
Prior to the development of high-throughput sequencing
methods, enhancers were largely identified by comparative
genomics, with the assumption that non-coding sequence
which is conserved between different vertebrate or mam-
malian species is enriched for enhancers [17, 18]. Using
this method in combination with functional assays, it was
found that about half of the identified, highly conserved
sequences are, indeed, functionally active enhancers.
However, this approach has some important limitations.
Some conserved sequences have no apparent enhancer
function when assayed in transgenic mice. Moreover, it is
now clear that a substantial fraction of cardiac enhancers
displays modest or no conservation across species [19–22].
With advances in high-throughput sequencing tech-
niques, new approaches have been developed to identify
gene enhancers [23]. Two types of strategies have been
used to identify cardiac enhancers: genome-wide distribu-
tion of key cardiac transcription factors and the
identification of appropriate epigenomic marks [16]. Each
strategy utilises ChIP-seq (chromatin immunoprecipitation
followed by high-throughput sequencing) and is indepen-
dent of cross-species sequence conservation. Both have
proved powerful in identifying cardiac enhancers, but both
have important limitations that we will summarise.
Experimental design and data analysis challenges
The genome-wide distribution of post-translational histone
modifications of chromatin, (or ‘‘chromatin marks’’) has
widely been used to predict enhancer activity [24]. The
identification of de novo mutations in histone-modifying
genes in CHD emphasizes the importance of chromatin
modification in cardiac differentiation [25]. The protocols
used to identify such marks are now well established and
multiple different marks have been identified, for example,
H3K4me1 correlates with gene promoters, H3K4me3 with
active promoters, H3k27me3 with inactive promoters, and
H3K27ac with some active enhancers. Importantly, there is
no single chromatin mark which can be used to identify all
active enhancers. Furthermore, new histone modifications
correlating with the presence of new classes of active
enhancers are identified regularly [26].
Another difficulty with this approach is the impact of
tissue contamination when ChIP-seq is undertaken with
cardiac tissue or with the whole organ. The heart contains a
large number of different cell types, (cardiomyocytes,
fibroblasts, endothelial and smooth muscle cells, and to
name a few) and their precise relative contributions have
been the subject of numerous debates [27]. Studies of
chromatin marks using cardiac tissue will, therefore,
identify an assortment of enhancer activities reflecting the
contribution of multiple cell types. Single-cell technology
offers a potential answer, but there are obvious technical
difficulties with the use of such small quantities of starting
material and no such study has yet been reported for car-
diac cells [28, 29]. Indeed, one limitation of the ChIP-seq
technique is the relatively large amount of initial material
required, due to low cellular DNA recovery rate. In a
single-cell experiment, non-specific binding of the anti-
body during the immunoprecipitation step leads to
experimental noise. New methods are currently being
developed to address this specific problem [30]. For
instance, microfluidic technologies have been developed to
isolate single cells into aqueous droplets, in which the
chromatin of individual cells is labelled with a unique
oligonucleotide barcode which can subsequently be
tracked. The tagged chromatin of hundred of cells is then
combined and undergoes the ChIP-seq procedure, allowing
reduction in noise associated with small input DNA.
Whilst the presence of chromatin marks has been shown
to be a powerful tool to identify enhancers, localisation of
key lineage-specific transcription factors has, in some
cases, been shown to be a better predictor of enhancer
activity [31]. The genome-wide distribution of those tran-
scription factors is not only of particular importance for
identifying their direct, downstream transcriptional targets,
but it also facilitates the identification of tissue-specific
enhancers. One significant advantage of using transcription
factor binding is in their potential cell specificity. If the
transcription factor is expressed in a cell-type specific
manner, for example, only in cardiomyocytes, cell-type
contamination will not affect in vivo analysis.
A large number of transcription factors have been shown
to be necessary for mouse heart development [32, 33].
Moreover, human mutations for most of those factors have
been suggested as the underlying cause of a variety of CHD
[34]. Numerous studies have recently addressed the gen-
ome-wide distribution of such key, cardiac transcription
factors (Table 1) [10, 20, 35–45]. What is striking is that
comparison of results reveals wide discrepancies in the
number of occupied sites identified in different studies, not
only between factors but also for the same factor at dif-
ferent stages (Table 1). It is not yet clear whether such
differences are biologically relevant, or simply reflects
differences in the methodology used, the data analysis
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methods chosen, and differences in the precise biological
model. What is clear is that a large number of parameters
can affect the identification of binding regions [46].
Many technical and methodological factors will affect
both the outcome of a ChIP-seq experiment and the extent
to which it can be compared with the other studies. The










Nkx2–5 E11.5 heart 2610 sc-8697 2 Input MACS GSE44576 Dupays et al. [36]
Adult heart 6705 sc-8697 1 Input In house GSE35151 Van Den Boogaard
et al. [10]
Hl-1 cells 20,573 Biotinylated antibody 1 Input Sole-search GSE21529 He et al. [37]
E12.5 hearts 16,899 sc-8697 1 Input MACS GSE70332 Ye et al. [45]
CP 8718 sc-8697 1 ChIP in
KO
In house GSE72223 Luna-Zurita et al. [40]
CM 25,381 sc-8697 1 ChIP in
KO
In house GSE72223 Luna-Zurita et al. [40]
Hl-1 cells 1534 DamID 3 Input CisGenome GSE44902 Bouveret et al. [35]
Gata4 Adult heart 1756 sc-1237 1 Input In house GSE35151 Van Den Boogaard
et al. [10]
Hl-1 cells 16,753 Biotinylated antibody 1 Input Sole-search GSE21529 He et al. [37]
E12.5
ventricles
43,800 Biotinylated antibody 2 Input MACS GSE52123 He et al. [20]
E12.5
ventricles
11,915 sc-1237 2 Input MACS GSE52123 He et al. [20]
Adult
ventricles
13,504 Biotinylated antibody 2 Input MACS GSE52123 He et al. [20]
CP 11,000 sc-1237 1 ChIP in
KO
In house GSE72223 Luna-Zurita et al. [40]
CM 10,641 sc-1237 1 ChIP in
KO
In house GSE72223 Luna-Zurita et al. [40]
Tbx5 Hl-1 cells 55,872 Biotinylated antibody 1 Input Sole-search GSE21529 He et al. [37]
CP 4985 sc-17866 1 ChIP in
KO
In house GSE72223 Luna-Zurita et al. [40]
CM 8952 sc-17866 1 ChIP in
KO
In house GSE72223 Luna-Zurita et al. [40]
Tbx20 Adult heart 4012 Anti-GFP, Tbx20 GFP
tagged
1 Input QuEST GSE29636 Shen et al. [41]
Tbx3 Adult heart 13,242 sc-17871 1 Input In house GSE35151 Van Den Boogaard
et al. [10]
Mef2a Hl-1 cells 1337 Biotinylated antibody 1 Input Sole-search GSE21529 He et al. [37]
Srf Hl-1 cells 23,806 Biotinylated antibody 1 Input Sole-search GSE21529 He et al. [37]
Isl1 Adult SAN 1483 39.4D5, DSHB 1 Input HOMER GSE68974 Liang et al. [39]
Pitx2 12-week
heart
11,280 Flag-M2 1 Input HOMER GSE47928 Tao et al. [42]
Hopx E9.5 heart 3775 Flag-M2 2 Input HOMER GSE67251 Jain et al. [38]
COUP-TFII E13.5 atria 2863 61214 1 IgG MACS GSE46498 Wu et al. [44]
Shox2 E12.5 hearts 14,271 Anti-HA 2 Input MACS GSE21529 Ye et al. [45]
Hey1 CM 17,874 Flag-M2 1 w/o dox MACS GSE60699 Weber et al. [43]
Hey2 CM 20,498 Flag-M2 1 w/o dox MACS GSE60699 Weber et al. [43]
p300 E11.5 heart 3597 SC-585 1 No QuEST GSE22549 Blow et al. [19]
Hl-1 cells 1491 Biotinylated antibody 1 Input Sole-search GSE21529 He et al. [37]
p2 hearts 6564 4771, cell signaling 1 Input MACS GSE32587 May et al. [21]
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quality of the primary antibody used to recognise the
transcription factor has been shown to be crucial, and
epitope-tagging has been used to address problems caused
by antibody variation and cross reactivity. This can have
dramatic results on ChIP-seq results. Comparison of data
obtained with an antibody against GATA4 versus a flag-
tagged GATA4 shows a dramatic increase in the number of
binding events (or ‘‘peaks’’) from 11,915 to 43,800 [20].
The number of biological replicates can also dramatically
affect the number of significant peaks identified. Pioneering
studies have largely used only a single biological sample, no
doubt partly due to the novelty of the technique and partly the
cost of sequencing (Table 1). However, as with all biological
analyses, multiple biological replicates have proved to be
necessary [46]. Interestingly, increasing from two to three
replicates does not appear to have significantly enhanced the
quality of results [46].
The number of sequence reads has been shown to be
critical for the identification of relevant peaks [47]. The
number of identified binding sites increases with
sequencing depth, since weaker binding sites become sta-
tistically significant with a greater number of reads [48].
Use of an appropriate control data set has also been shown
to be critical [49]. This generally comprises ‘‘Input’’’ DNA,
(DNA prepared under the same conditions as the
immunoprecipitated DNA) or an ‘‘IgG’’ control, (a ChIP
reaction performed with an unrelated antibody). The opti-
mum choice remains under discussion [50].
With the identification of thousands of putative enhan-
cers, limitations enforced by the need for experimental
validation of their function. Transgenic mouse reporter
assays are the most commonly used approach to evaluate
the function of enhancers in vivo. Such experiments consist
in delivering a linear plasmid containing a reporter gene
(for example, LacZ or GFP) linked to the putative enhancer
into the mouse zygote, through pronuclear injection [51].
The transgenic embryos generated, generally in a transient
manner, are assessed for the spatial expression of the
reporter gene in the whole embryo. However, if that
technique is a powerful way to identify qualitative enhan-
cer activity, copy number, and position effect due to
random transgene insertion impede reliable quantitative
analysis. Moreover, mouse transgenic experiments are
clearly not an appropriate technique for high-throughput
testing of enhancers identified with ChIP-seq, due to their
relatively high cost. Furthermore, in the context of dynamic
studies, in which an enhancer has to be tested at different
stages of development and/or different conditions of bio-
logical stress, this approach becomes extremely time-
consuming. Stable transgenic lines would most likely need
to be generated and studied in different conditions, sig-
nificantly increasing the time of study as well as escalating
an already high cost.
In summary, despite technological improvements which
have facilitated wider adoption of the technique, design
and analysis of ChIP-seq experiments remain challenging
and different choices can often lead to conflicting results
[52].
Dynamic of enhancers during cardiac development
If the number of studies describing the identification of
cardiac enhancers has been relatively high, the number of
studies describing the dynamics of those enhancers—their
differential usage between stages of development and/or in
disease conditions—has been relatively poor.
Early studies established that even if evolutionary
sequence conservation is a powerful tool to identify
enhancers, fewer than 2 % identified in this way are active
in the heart [17, 18]. Location of the transcriptional co-
activator p300 proved to be to be a powerful predictor of
enhancer activity in brain and limb [53] and this was,
therefore, used in the mouse heart at embryonic day 11
(E11.5) [19]. Results demonstrated that most candidate
cardiac enhancers identified by p300 binding are less
conserved in vertebrate evolution than those in limb or
brain [19].
Comparison of p300 binding between the foetal and
adult human heart shows that a large proportion of the
enhancers identified in this way are highly dynamic during
heart development [21]. Indeed, 48 % of human cardiac
enhancers active in the adult are also identified in foetal
hearts, whilst only 21 % of foetal cardiac enhancers are
identified with adult tissue [21]. Similar results are
obtained when comparing the embryonic (E14.5) and the
adult mouse heart, using the chromatin marks H3K4me1 or
H3K27ac [54]. Such dynamic enhancer usage appears to
reflect distinct biological function; enhancers specific to
embryonic stages are associated with genes expressed
during cardiac differentiation, whilst adult enhancers are
associated with genes important for adult heart function
[54].
Interestingly, comparison of enhancers (identified
through p300 binding) between the postnatal day 2 mouse
heart and the approximately equivalent 16-week-old
human foetal heart shows only a 21 % overlap. This sug-
gests a considerable and, perhaps, unexpected degree of
species specificity for cardiac enhancers [21]. Since even
poorly conserved human enhancers are able to drive car-
diac expression in a mouse cardiac transgenic assay, even
if enhancer usage between species is different, the cardiac
transcription factors that regulate those enhancers are most
probably the same [21].
Similarly dynamic activity of cardiac enhancers is found
comparing the chromatin mark H3K27ac at different stages
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of mouse heart development (E11.5, E14.5, E17.5, P0, P7,
P21, and P56) [22]. Indeed, only 3 % of cardiac enhancers
identified in this way are predicted to be active at all stages
examined. That extensive and fast turnover is illustrated
with only 45 % identified actives in at most two consecu-
tive time points [22]. The large majority of cardiac
enhancers identified in this way are predicted to have a
highly restricted, temporal window of activity during
development, which, in turn, suggests that dynamic
developmental processes are regulated by the transient
activities of such enhancers.
Interestingly, substantial differences are observed in
sequence conservation of putative enhancers within a given
tissue across time points and also across tissues at the same
timepoint [22]. As mentioned above, heart enhancers show
relatively weak conservation compared with enhancers
identified in either liver or more dramatically, forebrain.
However, it is interesting to note that this conservation is
not constant during development; enhancer conservation is
maximal at early stage of heart development when com-
pared with enhancers active in the adult heart [22].
As with heart development, enhancer usage during the
differentiation of ESCs into cardiomyocytes is also highly
dynamic [55]. Moreover, the distribution of four different
chromatin marks at four different stages of ESC differen-
tiation (ESC, mesoderm, cardiac progenitor, and
cardiomyocytes) shows that genes with similar expression
patterns can show substantial variation in chromatin states
during cardiac differentiation. These results suggest that
histone mark profile is not very useful for predicting
dynamics of gene expression [55].
Dynamic enhancer usage is also observed when the
binding of cardiac transcription factors, such as GATA4, is
used to identify heart enhancers [20]. 66.5 % of the adult
GATA4-bound regions are occupied by GATA4 in the
E12.5 foetal heart, whilst 80.1 % of foetal GATA4 regions
are not bound by GATA4 in the adult heart. Those pro-
portions are similar to those found by assaying chromatin
marks, with again, a much larger number of enhancers
predicted to be active during development than in the adult.
Furthermore, the authors also noted that GATA4 binding,
which is mainly distal to the transcription start site (TSS) in
the embryonic mouse heart, is shifted more proximal to the
TSS in the adult heart.
Foetal-specific, shared, and adult-specific GATA4
regions were associated with different co-enriched-binding
sites, with, for example, MEF2 and TEAD1 motifs enri-
ched in foetal-specific regions, whilst adult regions were
enriched for the EGR-1 motif. The functional consequence
of such association remains undocumented.
GATA4 binding is not only changed dynamically
between embryonic development and the adult heart, but
also in the pathological state of cardiac hypertrophy [20], a
condition in which GATA4 is well known to play a role
[56]. When hypertrophy of the heart is induced by pressure
overload, only 49 % of the GATA4 bound regions are
found shared between ascending aortic band and the sham
condition [20]. In pathological stress, such as pressure
overload, reactivation of a foetal gene expression pro-
gramme has been suggested to occur [57]. However, if
there is clearly a redistribution of GATA4 binding under
pathological stress, the redistribution to foetal-specific
enhancers is relatively small. Indeed, only 20.5 % of stress-
induced GATA4 binding was on foetal regions, whilst
40 % was to regions bound in neither foetal nor the adult
heart [20]. These results suggest that under pathological
hypertrophy, rather than reallocation to foetal enhancers,
GATA4 binds to a set of stress-specific, cardiac enhancers.
Similar results are found with the regulation of Nppa–Nppb
gene cluster during cardiac development and hypertrophy
[58]. Those two genes are induced by stress and are well-
described clinical markers of heart failure. In that study, the
distribution of H3K27ac and the association of Pol2 across
the locus reveal that foetal expression and stress-induced
Nppa expression is dependent on different enhancers, again
suggesting that the foetal and stress transcriptional regu-
latory networks are different [58].
As observed in vivo, the binding pattern of GATA4,
NKX2–5, and TBX5 is all highly dynamic during ESC
differentiation into cardiomyocytes [40]. During the tran-
sition of cardiac progenitors to cardiomyocytes in vitro,
more than 50 % of the binding events occur at a single,
specific stage [40]. Moreover, the same study highlights the
extensive co-binding of these cardiac transcription factors
on common enhancers regulating cardiac gene expression.
Interestingly, in a null background for NKX2–5, TBX5, or
both, a significant ectopic binding of the remaining factors
is observed [40]. This suggests that interdependent binding
may also be necessary to prevent transcription factors from
distributing ectopically and activating lineage-inappropri-
ate genes. Such a mechanism of ectopic reallocation of
transcription factor binding is also observed when the
genome distribution of the transcription factor NKX2–5 is
compared with that of a CHD-associated, mutated form of
the protein [35]. If NKX2–5 mutants’ proteins fail to bind
the majority of its wild-type targets in HL-1 cells, they are
still able to recognise a large number of them along with a
unique set of ectopic sites [35]. The significance of those
ectopic sites of binding in the genome is not yet clear, but
in the context of CHD, they could affect transcription in
either a positive or dominant negative manner [35].
Extensive co-binding of NKX2–5 has also been
observed with both TBX5 and SHOX2 [45]. In the E12.5
mouse heart, nearly 80 % of NKX2–5-bound regions
overlap with SHOX2 binding regions [45]. Extending that
co-occupancy analysis with a TBX5 data set published
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previously [37], the authors found that 67 % of the
SHOX2–NKX2–5 co-occupied sites are also occupied by
TBX5 [45]. Such significant co-occupancy of enhancers is
consistent with observations indicating an antagonising
role of SHOX2 on the transcriptional output of NKX2–5 in
the pulmonary vein of the developing heart [45].
Our own efforts to identify active cardiac enhancers in
the E11.5 mouse embryonic heart demonstrate that, at least
at this stage, this is achieved more effectively using
NKX2–5 binding than by p300 binding [19, 36]. 83 % of
enhancers enriched for NKX2–5 binding versus 53 % for
those enriched for p300 drive expression in the mouse
heart. This increase in efficiency is mainly due to a
reduction in the number of false positives. This suggests
that binding of a critical cardiac transcription factor is an
efficient predictor of cardiac enhancer activity, an obser-
vation consistent with the previous findings in equivalent
studies using blood cells [31].
Sequence analysis of NKX2–5-bound regions suggests
that NKX2–5 and MEIS1 share an overlapping-binding site
which is present in a number of cardiac enhancers in vivo
(Fig. 1). Interestingly, these two transcription factors are
sequentially expressed in the differentiating cardiac pro-
genitors of the embryo. As cardiac progenitor mature, they
experience successively high levels of MEIS1 in cardiac
progenitors, followed by high levels of NKX2–5 in dif-
ferentiated cardiomyocytes. This suggests a simple
mechanism of transcriptional regulation, in which one
factor successively replaces the other at cardiac enhancer
harbouring the shared-binding site (Fig. 1).
The mesodermal core of the branchial arches contains a
population of cardiac progenitor cells which populate the
outflow tract of the developing heart [59]. Strikingly,
nearly 30 % of NKX2–5-bound regions are also bound by
MEIS in the first branchial arch [60], suggesting that this
mechanism can be extended to an entire subset of cardiac
enhancers. A similar mechanism of transcriptional regula-
tion through an overlapping-binding site has been
described for the gene Fgf10 [61]. A cardiac enhancer of
that gene is successively bound by ISL1 and NKX2–5 [61].
That Fgf10 enhancer is activated in cardiac progenitors by
high levels of ISL1 and is repressed in the myocardium by
high levels of NKX2–5, which is likely to act both directly
and indirectly through Isl1 suppression [61]. Taken toge-
ther, these findings suggest that overlapping transcription
factor-binding sites in cardiac enhancers might be of broad
significance during the differentiation of cardiac progeni-
tors. Moreover, such a mechanism of replacement of one
transcription factor by another has been found in other
systems. When ESCs become specified to form neural
precursors and subsequently differentiate into neurons, an
ordered and sequential binding of Sox2, Sox3, and Sox11
to target enhancers drive neurogenesis. In this case, Sox2
binding would first preselect neural genes in ES cells,
ensuring their proper activation in neural precursors and
then inducing neuronal differentiation [62].
Conclusion
Recent progress in ChIP-seq techniques has allowed great
advances in the systemic identification of cardiac enhan-
cers active during cardiac development, as well as in the
normal and pathological adult heart. With the decrease in
cost and improvement in new technologies, such as single-

































































Fig. 1 Mechanism of transcriptional regulation by successive bind-
ing of MEIS1 and NKX2–5 on cardiac enhancers. NKX2–5 and
MEIS1 are able to bind in vitro on a DNA motif (GTGNTGACAG)
which is an overlapping-binding site for the two transcription factors.
As cardiac progenitors differentiate in the mouse embryo, they
successively experience high levels of MEIS1 expression in the
secondary heart field (grey) followed by high levels of NKX2–5
expression in the heart tube (red). Cardiac enhancers with an
overlapping-binding site for MEIS1 and NKX2–5 are bound succes-
sively by those factors
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pathological conditions as well as a more detailed spatial
resolution in the mouse embryonic heart should lead to a
better understanding of the gene regulatory network
responsible for cardiovascular development and
differentiation.
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